• Je něco špatně v tomto záznamu ?

Rifampicin Nanoformulation Enhances Treatment of Tuberculosis in Zebrafish

J. Trousil, Z. Syrová, NK. Dal, D. Rak, R. Konefał, E. Pavlova, J. Matějková, D. Cmarko, P. Kubíčková, O. Pavliš, T. Urbánek, M. Sedlák, F. Fenaroli, I. Raška, P. Štěpánek, M. Hrubý,

. 2019 ; 20 (4) : 1798-1815. [pub] 20190306

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20022782

Mycobacterium tuberculosis, the etiologic agent of tuberculosis, is an intracellular pathogen of alveolar macrophages. These cells avidly take up nanoparticles, even without the use of specific targeting ligands, making the use of nanotherapeutics ideal for the treatment of such infections. Methoxy poly(ethylene oxide)- block-poly(ε-caprolactone) nanoparticles of several different polymer blocks' molecular weights and sizes (20-110 nm) were developed and critically compared as carriers for rifampicin, a cornerstone in tuberculosis therapy. The polymeric nanoparticles' uptake, consequent organelle targeting and intracellular degradation were shown to be highly dependent on the nanoparticles' physicochemical properties (the cell uptake half-lives 2.4-21 min, the degradation half-lives 51.6 min-ca. 20 h after the internalization). We show that the nanoparticles are efficiently taken up by macrophages and are able to effectively neutralize the persisting bacilli. Finally, we demonstrate, using a zebrafish model of tuberculosis, that the nanoparticles are well tolerated, have a curative effect, and are significantly more efficient compared to a free form of rifampicin. Hence, these findings demonstrate that this system shows great promise, both in vitro and in vivo, for the treatment of tuberculosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022782
003      
CZ-PrNML
005      
20201214124810.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.biomac.9b00214 $2 doi
035    __
$a (PubMed)30785284
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Trousil, Jiří $u Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstí 2 , 162 00 Prague 6 , Czech Republic. Department of Analytical Chemistry, Faculty of Science , Charles University , Hlavova 8 , 128 43 Prague 2 , Czech Republic.
245    10
$a Rifampicin Nanoformulation Enhances Treatment of Tuberculosis in Zebrafish / $c J. Trousil, Z. Syrová, NK. Dal, D. Rak, R. Konefał, E. Pavlova, J. Matějková, D. Cmarko, P. Kubíčková, O. Pavliš, T. Urbánek, M. Sedlák, F. Fenaroli, I. Raška, P. Štěpánek, M. Hrubý,
520    9_
$a Mycobacterium tuberculosis, the etiologic agent of tuberculosis, is an intracellular pathogen of alveolar macrophages. These cells avidly take up nanoparticles, even without the use of specific targeting ligands, making the use of nanotherapeutics ideal for the treatment of such infections. Methoxy poly(ethylene oxide)- block-poly(ε-caprolactone) nanoparticles of several different polymer blocks' molecular weights and sizes (20-110 nm) were developed and critically compared as carriers for rifampicin, a cornerstone in tuberculosis therapy. The polymeric nanoparticles' uptake, consequent organelle targeting and intracellular degradation were shown to be highly dependent on the nanoparticles' physicochemical properties (the cell uptake half-lives 2.4-21 min, the degradation half-lives 51.6 min-ca. 20 h after the internalization). We show that the nanoparticles are efficiently taken up by macrophages and are able to effectively neutralize the persisting bacilli. Finally, we demonstrate, using a zebrafish model of tuberculosis, that the nanoparticles are well tolerated, have a curative effect, and are significantly more efficient compared to a free form of rifampicin. Hence, these findings demonstrate that this system shows great promise, both in vitro and in vivo, for the treatment of tuberculosis.
650    _2
$a zvířata $7 D000818
650    _2
$a modely nemocí na zvířatech $7 D004195
650    12
$a nosiče léků $x chemie $x farmakokinetika $x farmakologie $7 D004337
650    _2
$a lidé $7 D006801
650    12
$a makrofágy $x metabolismus $x mikrobiologie $7 D008264
650    _2
$a myši $7 D051379
650    _2
$a Mycobacterium tuberculosis $x růst a vývoj $7 D009169
650    12
$a nanočástice $x chemie $x terapeutické užití $7 D053758
650    _2
$a RAW 264.7 buňky $7 D000067996
650    12
$a rifampin $x chemie $x farmakokinetika $x farmakologie $7 D012293
650    _2
$a tuberkulóza $x farmakoterapie $x metabolismus $x patologie $7 D014376
650    _2
$a dánio pruhované $7 D015027
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Syrová, Zdeňka $u Institute of Biology and Medical Genetics, First Faculty of Medicine , Charles University and General University Hospital in Prague , Albertov 4 , 128 00 Prague 2 , Czech Republic.
700    1_
$a Dal, Nils-Jørgen K $u Department of Biosciences , University of Oslo , Blindernveien 31 , 0371 Oslo , Norway.
700    1_
$a Rak, Dmytro $u Institute of Experimental Physics , Slovak Academy of Sciences , Watsonova 47 , 040 01 Košice , Slovakia.
700    1_
$a Konefał, Rafał $u Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstí 2 , 162 00 Prague 6 , Czech Republic.
700    1_
$a Pavlova, Ewa $u Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstí 2 , 162 00 Prague 6 , Czech Republic.
700    1_
$a Matějková, Jana $u Department of Medical Microbiology, Second Faculty of Medicine , Charles University and Motol University Hospital , V Úvalu 84 , 150 06 Prague 5 , Czech Republic.
700    1_
$a Cmarko, Dušan $u Institute of Biology and Medical Genetics, First Faculty of Medicine , Charles University and General University Hospital in Prague , Albertov 4 , 128 00 Prague 2 , Czech Republic.
700    1_
$a Kubíčková, Pavla $u Center of Biological Defense , Military Health Institute, Military Medical Agency , 561 66 Těchonín , Czech Republic.
700    1_
$a Pavliš, Oto $u Center of Biological Defense , Military Health Institute, Military Medical Agency , 561 66 Těchonín , Czech Republic.
700    1_
$a Urbánek, Tomáš $u Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstí 2 , 162 00 Prague 6 , Czech Republic.
700    1_
$a Sedlák, Marián $u Institute of Experimental Physics , Slovak Academy of Sciences , Watsonova 47 , 040 01 Košice , Slovakia.
700    1_
$a Fenaroli, Federico $u Department of Biosciences , University of Oslo , Blindernveien 31 , 0371 Oslo , Norway.
700    1_
$a Raška, Ivan $u Institute of Biology and Medical Genetics, First Faculty of Medicine , Charles University and General University Hospital in Prague , Albertov 4 , 128 00 Prague 2 , Czech Republic.
700    1_
$a Štěpánek, Petr $u Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstí 2 , 162 00 Prague 6 , Czech Republic.
700    1_
$a Hrubý, Martin $u Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstí 2 , 162 00 Prague 6 , Czech Republic.
773    0_
$w MED00006456 $t Biomacromolecules $x 1526-4602 $g Roč. 20, č. 4 (2019), s. 1798-1815
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30785284 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214124810 $b ABA008
999    __
$a ok $b bmc $g 1595101 $s 1113458
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 20 $c 4 $d 1798-1815 $e 20190306 $i 1526-4602 $m Biomacromolecules $n Biomacromolecules $x MED00006456
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace